Organic cation (OC) transporters play important roles in the disposition and clearance of many endogenous and foreign OCs in the body. In contrast to the kidney and liver, little is known about OC elimination mechanisms in the brain. This is rather unfortunate because many CNS active compounds, including monoamine neurotransmitters (e.g. dopamine, serotonin), CNS drugs (e.g. amantadine, nicotine) and neurotoxins (e.g. 1-methyl-4-phenylpyridinium (MPP+)) are small hydrophilic OCs that rely on transporters to regulate their brain levels. This proposal focuses on plasma membrane monoamine transporter (PMAT), a novel brain OC transporter first cloned in our laboratory. While structurally related to the equilibrative nucleoside transporter family (SLC29), PMAT possesses a unique and surprisingly diverse substrate specificity, transporting structurally heterogeneous OCs such as biogenic amines, clinically used drugs and neurotoxins. In humans and rodents, PMAT is most abundantly expressed in the brain and highly concentrated in the blood-cerebrospinal fluid (CSF) barrier (i.e. BCSFB or choroid plexus). We hypothesized that PMAT is the principal OC transporter at the BCSFB and is responsible for removing a variety of endogenous and xenobiotic OCs from the brain.
Three Specific Aims (SAs) have been proposed. SA1 is focused on elucidating the molecular mechanisms governing transporter-substrate interactions to explain the unique and versatile substrate specificity of PMAT. SA2 is focused on elucidating the transport mechanism of PMAT and developing a cellular model for OC flux at the BCSFB. Lastly, in SA3, we will construct and validate a transgenic animal model, which will allow a variety of mechanistic studies to reveal the in vivo action of PMAT. We will apply several experimental methods, ranging from molecular biochemical techniques, computational biology, electrophysiology, immunohistochemistry to transgenic approach, to elucidate the structure, function and biological significance of PMAT in clearing neurotransmitters, drugs and toxins in the brain. The proposed studies have broad implications in our understanding of normal and pathophysiological functions of the brain. Detailed knowledge of OC transporters at the CNS barriers can also help to explain and predict the pharmacokinetics and pharmacodynamics of OC drugs and toxins in the CNS compartment and aid in the development of new strategies for drug targeting to the brain.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM066233-08
Application #
7860274
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Okita, Richard T
Project Start
2002-08-01
Project End
2012-08-31
Budget Start
2010-06-01
Budget End
2012-08-31
Support Year
8
Fiscal Year
2010
Total Cost
$268,408
Indirect Cost
Name
University of Washington
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wagner, David J; Duan, Haichuan; Chapron, Alenka et al. (2017) Potent inhibition of human organic cation transporter 2 (hOCT2) by ?-carboline alkaloids. Xenobiotica 47:1112-1120
Zha, Weibin; Ho, Horace T B; Hu, Tao et al. (2017) Serotonin transporter deficiency drives estrogen-dependent obesity and glucose intolerance. Sci Rep 7:1137
Yin, Jia; Duan, Haichuan; Wang, Joanne (2016) Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation. J Pharmacol Exp Ther 359:401-410
Shirasaka, Yoshiyuki; Lee, Nora; Duan, Haichuan et al. (2016) Interspecies comparison of the functional characteristics of plasma membrane monoamine transporter (PMAT) between human, rat and mouse. J Chem Neuroanat :
Wang, J (2016) The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition. Clin Pharmacol Ther 100:489-499
Wagner, David J; Hu, Tao; Wang, Joanne (2016) Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res 111:237-246
Yin, Jia; Wang, Joanne (2016) Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B 6:363-373
Shirasaka, Yoshiyuki; Lee, Nora; Zha, Weibin et al. (2016) Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice. Drug Metab Pharmacokinet 31:385-388
Duan, Haichuan; Hu, Tao; Foti, Robert S et al. (2015) Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors. Drug Metab Dispos 43:1773-80
Yin, Jia; Duan, Haichuan; Shirasaka, Yoshiyuki et al. (2015) Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins. Drug Metab Dispos 43:1872-81

Showing the most recent 10 out of 36 publications